Eilber F R, Morton D L
AJR Am J Roentgenol. 1976 May;126(5):1082-7. doi: 10.2214/ajr.126.5.1082.
Growth of malignant tumors of the head and neck has been associated with progressive impairment of immunologic activity. Successful control of disease has been shown to reverse this defect. Preliminary results of a nonrandomized trial reduced recurrence of head and neck cancer for a median time of 11.5 months in eight of 10 patients who received chemoimmunotherapy adjuvant to surgical resection or radiation treatment. The number of patients in the series was small and the followup time too short to determine the length of effectiveness for this treatment. Based on these results, a new protocol has been initiated to randomize patients with advanced T3 and T4 lesions into groups for comparison of adjuvant chemotherapy alone with adjuvant chemoimmunotherapy.
头颈部恶性肿瘤的生长与免疫活性的进行性损害有关。已证明成功控制疾病可逆转这一缺陷。一项非随机试验的初步结果显示，在接受手术切除或放射治疗辅助化疗免疫治疗的10名患者中，有8名患者头颈部癌复发的中位时间减少了11.5个月。该系列中的患者数量较少，随访时间太短，无法确定这种治疗的有效时长。基于这些结果，已启动一项新方案，将患有晚期T3和T4病变的患者随机分组，以比较单纯辅助化疗与辅助化疗免疫治疗的效果。
